유럽의 단백질체학 시장 : 제공, 용도, 국가별 분석 및 예측(2025-2035년)

This report can be delivered in 2 working days.

Introduction to Europe Proteomics Market

The Europe proteomics market is projected to reach $24.36 billion by 2035 from $6.91 billion in 2024, growing at a CAGR of 12.25% during the forecast period 2025-2035. Advances in high-resolution mass spectrometry and next-generation sequencing technologies are increasing proteomics usage in Europe, allowing for deeper and more precise protein analysis. Demand is being further increased by the region's increasing emphasis on personalized healthcare, which is being fueled by initiatives to find new biomarkers and improve disease-profiling skills. The development of new proteomic applications is developing quickly thanks to strong EU-backed research funding, public-private partnerships, and strategic alliances between hospitals, biotech companies, and academic institutions. Improved diagnostics and early-detection technologies are becoming more and more necessary as Europe's population ages and the prevalence of chronic illnesses rises. When taken as a whole, these factors are establishing proteomics as a fundamental component of clinical innovation and a major force behind the ecosystem of life-science research in the area.

Market Introduction

Advances in high-resolution mass spectrometry and next-generation sequencing technologies are increasing proteomics usage in Europe, allowing for deeper and more precise protein analysis. Demand is being further increased by the region's increasing emphasis on personalized healthcare, which is being fueled by initiatives to find new biomarkers and improve disease-profiling skills. The development of new proteomic applications is developing quickly thanks to strong EU-backed research funding, public-private partnerships, and strategic alliances between hospitals, biotech companies, and academic institutions. Improved diagnostics and early-detection technologies are becoming more and more necessary as Europe's population ages and the prevalence of chronic illnesses rises. When taken as a whole, these factors are establishing proteomics as a fundamental component of clinical innovation and a major force behind the ecosystem of life-science research in the area.

Across the region, the push toward personalised healthcare is accelerating the adoption of proteomics in oncology, neurology, cardiology, and chronic disease management. The development of next-generation proteomic applications is being accelerated by national innovation awards, EU-funded research initiatives, and cross-border partnerships between hospitals, biotech firms, academic institutions, and CROs. This robust financing ecosystem promotes standardization, data interoperability, and clinical validation of proteomic procedures in addition to supporting scientific innovation.

The need for early detection techniques, predictive biomarkers, and more focused treatment approaches is growing as Europe's population ages and the prevalence of chronic diseases rises. Proteomics is therefore becoming recognized as a key facilitator of better patient outcomes and healthcare effectiveness. Europe is well-positioned to spearhead the next generation of clinical and technological developments in proteomics thanks to its strong infrastructure, quality-focused regulations, and developed research environment.

Market Segmentation:

Segmentation 1: By Offering

• Sample Preparation
• Proteomics Technologies
  • Reagents and Consumables
  • Instruments
  • Software
• Proteomics Services

Segmentation 2: By Application

• Biomarker Discovery and Validation
• Proteome Profiling and Mapping
• Drug Discovery and Development
• Companion Diagnostics
• Protein-Protein Interactions

Segmentation 3: By Region

• Europe

Europe Proteomics Market Trends, Drivers and Challenges

Trends

• Growing shift from discovery proteomics to clinical and translational applications, especially in oncology and neurology.
• Rapid adoption of advanced mass spectrometry, single-cell proteomics, and high-throughput protein analysis platforms.
• Expansion of proteomics-based diagnostics and companion biomarker development supporting precision medicine.
• Increasing collaborations among universities, hospitals, biotech firms, and EU-funded research networks.
• Rising focus on integrated multi-omics workflows combining genomics, transcriptomics, and proteomics.

Drivers

• Strong EU funding programs and national research grants accelerating proteomics innovation.
• High demand for early-detection tools, disease stratification, and personalized treatment pathways.
• Advanced healthcare infrastructure and widespread adoption of digital health solutions.
• Growing R&D investment from biotech, pharma, and CROs in biomarker discovery and therapeutic development.
• Increased emphasis on standardization, quality control, and validated clinical proteomics pipelines.

Challenges

• Stringent regulatory frameworks, including IVDR compliance, increasing cost and time to market.
• Shortage of skilled proteomics experts and bioinformaticians across several European regions.
• High cost of advanced instrumentation and maintenance, limiting adoption in smaller labs.
• Fragmented data integration across multi-omics platforms and healthcare systems.
• Slow commercialization and reimbursement barriers for proteomics-based diagnostics.

How can this report add value to an organization?

Product/Innovation: This report enables organizations to identify high-value opportunities in the Europe proteomics market. It guides R&D investment strategies, technology adoption, and pipeline optimization, helping companies prioritize initiatives that accelerate biomarker discovery, disease diagnostics, and therapeutic development. By highlighting emerging technologies, strategic collaborations, and platform scalability, this report helps organizations strengthen their competitive positioning and capitalize on the rapid expansion of proteomics across research, clinical, and pharmaceutical applications.

Growth/Marketing: The report delivers in-depth insights into regional adoption trends, emerging markets, and partnership opportunities, supporting strategic market entry and commercialization planning. It enables companies to identify growth potential across offering, technology, application, and end-user segments. By understanding regional R&D investments, regulatory frameworks, and technology adoption rates, organizations can refine marketing, licensing, and collaboration strategies, maximize visibility, and increase return on investment in a competitive global landscape.

Competitive: This report provides comprehensive company profiling, competitive benchmarking, highlighting strategic collaborations, funding activities, mergers, acquisitions, and technology adoption trends. Stakeholders gain a clear understanding of competitor focus areas, R&D priorities, and market positioning. This intelligence allows organizations to identify gaps, anticipate market shifts, and formulate strategies to differentiate themselves, optimize market entry, and maintain leadership in the proteomics ecosystem.

Table of Contents

Executive Summary

Scope and Definition

1 Market: Industry Outlook

• 1.1 Market Overview and Ecosystem
• 1.2 Comparative Advantages and Disadvantages of Proteomics Over Other Omics
• 1.3 Supply Chain Analysis
• 1.4 Market Dynamics
  • 1.4.1 Trends, Drivers, Challenges, and Opportunities: Current and Future Impact Assessment, 2024-2035
• 1.5 Trends
  • 1.5.1 Increasing Automation for End-to-End Proteomics Workflow
  • 1.5.2 Growing Proteomics Research to Identify Disease Biomarkers
  • 1.5.3 Significant Number of Collaborations among Market Players
• 1.6 Market Dynamics
  • 1.6.1 Market Drivers
    • 1.6.1.1 Rising Prevalence of Chronic Diseases
    • 1.6.1.2 Continuous Technological Advancements
    • 1.6.1.3 Increasing Demand for Personalized Medicine
  • 1.6.2 Market Challenges
    • 1.6.2.1 High Costs of Acquisition Hindering the Adoption of Proteomics Technologies
    • 1.6.2.2 Shortage of Skilled Professionals
  • 1.6.3 Business Strategies
    • 1.6.3.1 Key Product Launch/Expansion
  • 1.6.4 Corporate Strategies
    • 1.6.4.1 Key Partnerships
    • 1.6.4.2 Key Funding and Grants
    • 1.6.4.3 Key Merger and Acquisitions
  • 1.6.5 Market Opportunities
    • 1.6.5.1 Expanding Proteomics Market in Emerging Regions through Affordable Technologies
• 1.7 Regulatory Landscape/Compliance
  • 1.7.1 Europe
    • 1.7.1.1 Regulatory Requirements for Proteomics Products Intended as Medical Devices
      • 1.7.1.1.1 EU Medical Device Regulation
      • 1.7.1.1.2 EU In Vitro Diagnostic Regulation
      • 1.7.1.1.3 Regulatory Requirements for Clinical Proteomics Labs in the EU
• 1.8 Patent Analysis
  • 1.8.1 Patent Analysis (by Year)
  • 1.8.2 Patent Analysis (by Country)

2 Region

• 2.1 Regional Summary
• 2.2 Europe
  • 2.2.1 Regional Overview
  • 2.2.2 Driving Factors for Market Growth
  • 2.2.3 Factors Challenging the Market
  • 2.2.4 By Offering
    • 2.2.4.1 By Proteomics Technologies
  • 2.2.5 By Application
  • 2.2.6 By Country
    • 2.2.6.1 U.K.
      • 2.2.6.1.1 By Offering
      • 2.2.6.1.2 By Application
    • 2.2.6.2 Germany
      • 2.2.6.2.1 By Offering
      • 2.2.6.2.2 By Application
    • 2.2.6.3 France
      • 2.2.6.3.1 By Offering
      • 2.2.6.3.2 By Application
    • 2.2.6.4 Italy
      • 2.2.6.4.1 By Offering
      • 2.2.6.4.2 By Application
    • 2.2.6.5 Spain
      • 2.2.6.5.1 By Offering
      • 2.2.6.5.2 By Application
    • 2.2.6.6 Rest-of-Europe
      • 2.2.6.6.1 By Offering
      • 2.2.6.6.2 By Application

3 Markets - Competitive Benchmarking & Company Profiles

• 3.1 Company Profile
  • 3.1.1 DiaSorin S.P.A.
    • 3.1.1.1 Overview
    • 3.1.1.2 Top Products/Product Portfolio
    • 3.1.1.3 Top Competitors
    • 3.1.1.4 Target Customers
    • 3.1.1.5 Key Personal
    • 3.1.1.6 Analyst View

4 Research Methodology

• 4.1 Data Sources
  • 4.1.1 Primary Data Sources
  • 4.1.2 Secondary Data Sources
  • 4.1.3 Data Triangulation
• 4.2 Market Estimation and Forecast